1. Prescription Fish Oil: 5 Things to Know  Medscape
  2. Fish-oil-derived drug fails in massive final phase human trial  New Atlas
  3. View full coverage on Google News
With one prescription fish oil, Vascepa, getting an indication for cardiovascular risk reduction in some patients with elevated triglycerides, what do you need to know about these products?With one prescription fish oil, Vascepa, getting an indication for cardiovascular risk reduction in some patients with elevated triglycerides, what do you need to know about these products?

Prescription Fish Oil: 5 Things to Know

A Phase 3 clinical trial into the efficacy of a fish-oil-derived drug called Epanova has been discontinued. The trial was designed to establish the use of the drug, a formulation of two omega-3 fatty acids, as an adjunct to statins for heart disease.Pharma company AstraZeneca has discontinued a large Phase 3 clinical trial into the efficacy of a fish-oil-derived drug called Epanova. The drug had been previously approved by the FDA to treat patients with very high triglyceride levels but this trial was designed to establish the broader use of the drug as an adjunct to conventional statin therapy for heart disease.

Fish-oil-derived drug fails in massive final phase human trial